End-to-End Supply Chain Insight
Content
Pharma Logistics IQ Reports
White Papers
Articles
News
Videos
Webinars
Glossary
Events
Pharma IQ Live - Free Online Events
Webinars
Conferences
Sponsorship
Media Kit
Contact Us
Our Sponsors
About
About Pharma Logistics IQ
Meet the Team
Contact Us
Advisory Board
Contributors
Pharma IQ App
Pharma IQ Network
Sign In
Sign Up
Logistics
Packaging & Labelling
Packaging & Shipping Systems
Regulations
Supply Chain Security – Track & Trace
Filter Categories
Logistics
Packaging & Labelling
Packaging & Shipping Systems
Regulations
Supply Chain Security – Track & Trace
Content
Pharma Logistics IQ Reports
White Papers
Articles
News
Videos
Webinars
Glossary
Events
Pharma IQ Live - Free Online Events
Webinars
Conferences
Sponsorship
Media Kit
Contact Us
Our Sponsors
About
About Pharma Logistics IQ
Meet the Team
Contact Us
Advisory Board
Contributors
Pharma IQ App
Pharma IQ Network
Sign In
Sign Up
Dyzle's CEO and CTO on Trends in Temperature Controlled Logistics
Add bookmark
Pharma Logistics Editor
02/15/2013
Bert Zandhuis, CEO and Rene Tjong Tjin Tai, CTO at Dyzle speaking at Cool Chain Logistics Europe 2013 in Basel, Switzerland, about trends in temperature controlled logistics and being smart with data.
Tags:
Bert Zandhuis
Rene Tjong Tjin Tai
Dyzle
data mangement
supply chain data management
supply chain
cold chain
cool chain logistics Europe
Recommended
Online
Seven steps to ensure you are GDP-inspection ready
Online
Bringing IDMP to life for patients: progress in 2019/2020
Online
Three reasons to digitally transform Regulatory Affairs
Online
A guideline for EUFMD implementation
Online
Brexit risk to European medicine supply 'revised down'
Online
New EU clinical trial guidelines lays down the principles for the two-step relea...
Online
Record year forecasted for pharmaceutical air shipments
Online
Pharma Logistics Compliance: 2018 Report
Online
GDP compliance alerts sounded
Online
2018 Trends to disrupt pharma supply chains
Online
EU launches new GMP guidelines
Online
EU transportation loophole could compromise drug quality